Free tool
FAERS Monitor: Inbrija
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209184 or its brand name (Inbrija, Levodopa). Reports on generic versions are filed under their own applications.
Reports
12,511
Serious
6,194
50% of reports
Hospitalization
2,791
Death reported
1,389
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cough2,350
- drug ineffective1,474
- parkinson^s disease1,081
- condition aggravated818
- dyskinesia785
- death733
- fall732
- device issue721
- hallucination674
- product residue present571
- tremor554
- device difficult to use523
- fatigue472
- dizziness469
- device use issue463
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 36 |
| 2005 | 38 |
| 2006 | 65 |
| 2007 | 69 |
| 2008 | 104 |
| 2009 | 93 |
| 2010 | 120 |
| 2011 | 109 |
| 2012 | 116 |
| 2013 | 147 |
| 2014 | 200 |
| 2015 | 273 |
| 2016 | 259 |
| 2017 | 357 |
| 2018 | 507 |
| 2019 | 1,516 |
| 2020 | 1,885 |
| 2021 | 2,286 |
| 2022 | 1,630 |
| 2023 | 507 |
| 2024 | 531 |
| 2025 | 662 |
| 2026 | 1,001 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,648 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product residue presentSignal | 571 | 199.0 | 182.7 | 100,414 |
| device use issueSignal | 463 | 45.7 | 41.7 | 19,670 |
| dyskinesiaSignal | 785 | 33.1 | 30.9 | 23,974 |
| hallucinationSignal | 674 | 15.2 | 14.1 | 8,853 |
| coughSignal | 2,350 | 14.2 | 13.7 | 28,963 |
| device issueSignal | 721 | 13.6 | 12.7 | 8,384 |
| device difficult to useSignal | 523 | 13.4 | 12.3 | 5,951 |
| tremorSignal | 554 | 5.6 | 5.2 | 2,113 |
| condition aggravatedSignal | 818 | 4.5 | 4.2 | 2,275 |
| fallSignal | 732 | 3.7 | 3.5 | 1,462 |
| drug ineffective | 1,474 | 1.9 | 1.8 | 647 |
| dizziness | 469 | 1.6 | 1.4 | 102 |
| death | 733 | 1.4 | 1.3 | 99 |
| fatigue | 472 | 1.0 | 0.9 | 0 |
| parkinson^s disease | 1,081 | 0.0 | 0.0 | 1,816,493 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.